In breast cancer cells, PTPN9 directly dephosphorylates EGFR and ErbB2, attenuating downstream STAT3/STAT5 signaling, suggesting that PTPN9 status could influence responses to EGFR-directed TKIs [45, 46]. Here, ERBB2 is linked to breast carcinoma.